Related Experiment Videos
Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide
1Department of Pediatrics, University of Nebraska Medical Center, Omaha 68198-5190.
Insights
A five-year-old boy with severe pulmonary hemorrhage due to primary pulmonary hemosiderosis and cow's milk sensitivity responded well to cyclophosphamide. This therapy proved life-saving for refractory cases when other treatments failed.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Hematology
Background:
- Primary pulmonary hemosiderosis is a rare condition causing lung bleeding.
- Cow's milk sensitivity can exacerbate pulmonary conditions in children.
- Refractory cases often require alternative treatment strategies.
Observation:
- A five-year-old boy presented with severe pulmonary hemorrhage.
- The patient had diagnosed primary pulmonary hemosiderosis and cow's milk sensitivity.
- Initial treatment with corticosteroids and azathioprine was ineffective.
Findings:
- Cyclophosphamide administration led to dramatic clinical improvement.
- Discontinuation of cyclophosphamide resulted in relapse of bleeding.
- Reinstitution of cyclophosphamide achieved significant recovery and sustained remission for five years.
- Treatment with cyclophosphamide for 14 months showed no adverse effects.
Implications:
- Cyclophosphamide represents a potential life-saving therapy for refractory pulmonary hemorrhage in primary pulmonary hemosiderosis.
- This case highlights the importance of considering immune-mediated triggers and novel therapeutic agents.
- Further research into cyclophosphamide's efficacy and safety in pediatric pulmonary hemorrhage is warranted.
Abstract:
This report describes a five-year-old boy with severe pulmonary hemorrhage caused by primary pulmonary hemosiderosis with cow's milk sensitivity. After failing to respond to corticosteroids and azathioprine, he dramatically improved after being given cyclophosphamide. He worsened after discontinuation of cyclophosphamide on two occasions and improved significantly with its reinstitution. Cyclophosphamide was continued for 14 months without further bleeding or adverse effects. The patient has remained in remission for nearly five years. Cyclophosphamide may be a life-saving alternative therapy for refractory pulmonary hemorrhage with pulmonary hemosiderosis.